Immune and inflammatory cytokines profile in Iraqi patients with acute and chronic myeloid leukemia


  • Shatha M. J. AL-Khateeb
  • Noor Thair Tahir
  • Ali Abdulateef Hasan Al-bayati



Acute Myeloid Leukemia, Chronic Myeloid Leukemia, IL-6, TNF?, IL-2


Introduction and Aim: Evaluation of the profile of immunological and inflammatory cytokines, IL-6, IL-2 and TNF? in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) patients compared their level with healthy controls, and assessment of the association of these cytokines with clinical and hematological variables.


Patients and Methods: Thirty AML, thirty CML patients, and thirty healthy control individuals were recruited for this study from the National Hematology Center for Research and Treatment in Baghdad for the period of October 2020 to March 2021. Leukemic patients were under chemotherapy. Complete blood picture routine test and cytokines profile test were done. IL-6, IL-2 and TNF-? were quantitatively measured using enzymes linked immunosorbent assay (ELISA) kits.


Results: Hematological myeloid cancers affect more males than female, in AML male/female ratio was 17/13 while in CML was 16/14. The range of duration of the disease for both AML and CML was 1-3 years. in both AML group the level of IL-6 59.66 ± 31.99 pg/mL and in CML group 57.07± 16.52 pg/mL were both significantly higher P value < 0.001 than that of control group 37.95± 6.10 pg/mL. TNF? in AML group was significantly higher P value < 0.001 than that of control group. A high significant difference in serum level of IL-2 P value <0.0001 in AML and CML compared to controls.


Conclusion: IL-6, TNF? and IL-2 levels were higher in myeloid malignancy groups than controls. Serum cytokines shown to be positively associated with each other and could signify to poor outcome of the myeloid malignancy patients.

Author Biographies

Shatha M. J. AL-Khateeb

Department of Chemistry and Biochemistry, College of Medicine, Al- Mustansiriyah University, Baghdad, Iraq


Noor Thair Tahir

National Diabetes center/ Mustansiriyah University, Baghdad, Iraq.


Ali Abdulateef Hasan Al-bayati

Department of Chemistry and Biochemistry, College of Medicine, Al- Mustansiriyah University, Baghdad, Iraq


Elena, C., Gallì, A., Bono, E., Todisco, G., Malcovati, L. J. Clonal hematopoiesis and myeloid malignancies: clonal dynamics and clinical implications. Current Opinion in Hematology. 2021; 28(5): 347-355.

Barbui, T., Thiele, J., Gisslinger, H., Kvasnicka, H. M., Vannucchi, A. M., Guglielmelli, P., et al., The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood cancer journal. 2018; 8(2): 1-11.

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., Jemal, A. J. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. a cancer journal for clinicians. 2018; 68(6): 394-424.

Hussain, A. M., Lafta, R. K. Cancer Trends in Iraq 2000–2016. Oman medical journal. 2021; 36(1): e219.

Soyfer, E. M., Fleischman, A. G. Oncology, P. Inflammation in Myeloid Malignancies: From Bench to Bedside. Journal of Immunotherapy Precision Oncology. 2021; 4(3): 160-167.

Craver, B. M., El Alaoui, K., Scherber, R. M., Fleischman, A. G. The critical role of inflammation in the pathogenesis and progression of myeloid malignancies. Cancers. 2018; 10(4): 104.

Binder, S., Luciano, M., Horejs-Hoeck, J. J. The cytokine network in acute myeloid leukemia (AML): a focus on pro-and anti-inflammatory mediators. Cytokine growth factor reviews. 2018; 43: 8-15.

Nievergall, E., Reynolds, J., Kok, C., Watkins, D., Biondo, M., Busfield, S., et al., TGF-? and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy. Leukemia. 2016; 30(6): 1263-1272.

Gallipoli, P., Pellicano, F., Morrison, H., Laidlaw, K., Allan, E. K., Bhatia, R., et al., Autocrine TNF-? production supports CML stem and progenitor cell survival and enhances their proliferation. The Journal of the American Society of Hematology. 2013; 122(19): 3335-3339.

Cimino, G., Amadori, S., Cava, M., De Sanctis, V., Petti, M., Di Gregorio, A., et al., Serum interleukin-2 (IL-2), soluble IL-2 receptors and tumor necrosis factor-alfa levels are significantly increased in acute myeloid leukemia patients. Leukemia. 1991; 5(1): 32-35.

Baldridge, M. T., King, K. Y., Goodell, M. A. Inflammatory signals regulate hematopoietic stem cells. Trends in immunology. 2011; 32(2): 57-65.

Olnes, M. J., Sloand, E. M.Targeting immune dysregulation in myelodysplastic syndromes. Jama. 2011; 305(8): 814-819.

Yahya, D. J., Al-Maaroof, Z. W., Hassoon, A. F. Evaluation of leukemia inhibitory factor, interleukin6 and leptin in acute and chronic myeloid leukemia in Babylon Province. Medical Journal of Babylon. 2016; 13(2): 513-521.

Mjali, A., Al-Shammari, H. H. J., Abbas, N. T., Azeez, Z. D., Abbas, S. K. Leukemia epidemiology in Karbala province of Iraq. Asian Pacific Journal of Cancer Care. 2019; 4(4): 135-139.

Camacho, V., Kuznetsova, V., Welner, R. S. Inflammatory Cytokines Shape an Altered Immune Response During Myeloid Malignancies. Frontiers in Immunology. 2021; 12.

Möller, B., Villiger, P. M., editors. Inhibition of IL-1, IL-6, and TNF-? in immune-mediated inflammatory diseases. Springer seminars in immunopathology; 2006: Springer.

Reynaud, D., Pietras, E., Barry-Holson, K., Mir, A., Binnewies, M., Jeanne, M., et al., IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer cell. 2011; 20(5): 661-673.

Säily, M., Koistinen, P., Savolainen, E.-R. The soluble form of interleukin-6 receptor modulates cell proliferation by acute myeloblastic leukemia blast cells. Annals of hematology. 1999; 78(4): 173-179.

Sanchez-Correa, B., Bergua, J. M., Campos, C., Gayoso, I., Arcos, M. J., Bañas, H., et al., Cytokine profiles in acute myeloid leukemia patients at diagnosis: survival is inversely correlated with IL-6 and directly correlated with IL-10 levels. Cytokine. 2013; 61(3): 885-891.

Zbaar, S. A. Serum level of TNF-alpha in patients with chronic myeloid leukemia on Imatinib therapy. Tikr Med J. 2017; 22: 54-60.

Gotlib, J. J. World Health Organization?defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management. American journal of hematology. 2012; 87(9): 903-914.

Malkovský, M., Sondel, P. J. Interleukin 2 and its receptor: structure, function and therapeutic potential. Blood reviews. 1987; 1(4): 254-266.

Nakase, K., Kita, K., Kyo, T., Tsuji, K., Katayama, N. J. High serum levels of soluble interleukin-2 receptor in acute myeloid leukemia: correlation with poor prognosis and CD4 expression on blast cells. Cancer epidemiology. 2012; 36(5): e306-e309.

Panteli, K. E., Hatzimichael, E. C., Bouranta, P. K., Katsaraki, A., Seferiadis, K., Stebbing, J., et al., Serum interleukin (IL)?1, IL?2, sIL?2Ra, IL?6 and thrombopoietin levels in patients with chronic myeloproliferative diseases. British journal of haematology. 2005; 130(5): 709-715.

Kornblau, S. M., McCue, D., Singh, N., Chen, W., Estrov, Z., Coombes, K. R. J. B., The Journal of the American Society of Hematology Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. The Journal of the American Society of Hematology. 2010; 116(20): 4251-4261.

Ostrand-Rosenberg, S. J. Myeloid-Derived Suppressor Cells: Facilitators of Cancer and Obesity-Induced Cancer. Annual Review of Cancer Biology. 2021; 5: 17-38.




How to Cite

M. J. AL-Khateeb S, Thair Tahir N, Al-bayati AAH. Immune and inflammatory cytokines profile in Iraqi patients with acute and chronic myeloid leukemia. Biomedicine [Internet]. 2022 May 1 [cited 2022 Nov. 27];42(2):262-7. Available from:



Original Research Articles

Plum Analytics